Omayma Alshaarawy

Omayma Alshaarawy

Auto-generated profile, based on publicly available information

Omayma Alshaarawy

Department of Family Medicine, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Environment International
Verified
Journal Article
Closed access
OAOmayma Alshaarawy
Omayma Alshaarawy
HEHosam A. Elbaz
Hosam A. Elbaz
MAMichael E. Andrew
Michael E. Andrew

1 October 2013 in Environmental Research
Verified
Journal Article
Closed access
OAOmayma Alshaarawy
Omayma Alshaarawy
MZMotao Zhu
Motao Zhu
ADAlan M Ducatman
Alan M Ducatman
BCBaqiyyah Conway
Baqiyyah Conway
MAMichael E. Andrew
Michael E. Andrew

1 August 2016 in Journal Of Hypertension
Verified
Journal Article
Closed access
OAOmayma Alshaarawy
Omayma Alshaarawy
HEHosam A. Elbaz
Hosam A. Elbaz
Objective: Preclinical studies have reported acute cardiovascular effects of cannabis, including a dose-dependent increase in blood pressure (BP), whereas orthostatic hypotension may follow as a result of decreased vascular resistance. In case reports, evidence links cannabis with acute cardiovascular events in young and middle-aged adults. Here, we offer epidemiologic estimates on cannabis use and BP levels association from the US National Health and Nutrition Examination Surveys 2005–2012 (n = 12 426). Methods: Computer-assisted self-interviews assessed cannabis use. BP was determined by an average of up to four measurements taken during a single examination. Regression modeling was used to examine cannabis use and BP association. Results: Recently active cannabis use was associated with increase in SBP (β = 1.6; 95% confidence interval: 0.6, 2.7) in the age–sex-adjusted model. Additional covariate adjustment did not affect the positive association. No association between cannabis use and DBP was detected. Conclusion: A modest association between recent cannabis use and SBP was detected among a relatively large nationally representative sample of US adults. With the legalization of cannabis, there is a need for preclinical, clinical and prospective population-based research on the cardiovascular effects of cannabis use.

16 March 2019 in International Journal of Epidemiology
Verified
Journal Article
Closed access
OAOmayma Alshaarawy
Omayma Alshaarawy
JAJames C Anthony
James C Anthony
Background: Pre-clinical studies indicate increased food intake and weight gain as cannabinoid effects. Cross-sectional epidemiological studies, however, indicate lower prevalence of obesity among cannabis users. Here, we aim to study the weight-gain research question in the prospectively conducted National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Methods: NESARC was designed to produce nationally representative estimates for the US population. Participants (aged 18+) completed computer-assisted personal interviews on cannabis use, body weight and height at Waves 1 (W1, 2001–02) and 2 (W2, 2004–05). General linear modelling yields estimates for change in body mass index (BMI) regressed on cannabis-use status, with covariate adjustment based on a conceptual model for BMI determinants (n = 33 000). Results: At W2, 77% of the participants never used cannabis, 18% had discontinued use (‘quit’), 3% were initiates and 2% were persistent users. Estimated W1-to-W2 BMI change shows an increase for all subgroups. Compared with never-users (reference), inverse slope estimates and attenuated change (%) in BMI between W1 and W2 are seen for cannabis-use subgroups: quitters [β = –0.81; 95% confidence interval (CI) = –1.01, –0.60], initiates (β = –0.97; 95% CI = –1.36, –0.57) and persistent users (β = –1.26; 95% CI = –1.81, –0.72). Conclusion: This new prospective study builds from anecdotes, pre-clinical studies and cross-sectional evidence on inverse associations linking cannabis use and obesity and shows an inverse cannabis–BMI increase association. Confirmatory studies with rigorous cannabis and BMI assays will be needed.

1 January 2017 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
JAJames C. Anthony
James C. Anthony
CLCatalina Lopez-Quintero
Catalina Lopez-Quintero
OAOmayma Alshaarawy
Omayma Alshaarawy
Background: Globally, the most widely used set of compounds among the internationally regulated drugs is cannabis. Objective: To review evidence from epidemiological research on cannabis, organized in relation to this field's five main rubrics: quantity, location, causes, mechanisms, and prevention/ control. Method: The review covers a selection of evidence from standardized population surveys, official statistics, and governmental reports, as well as published articles and books identified via MEDLINE, Web of Science, and Google Scholar as of July 2016. Results: In relation to quantity, an estimated 3% to 5% of the world population is thought to have tried a cannabis product, with at least one fairly recent use, mainly extra-medical and outside boundaries of prescribed use. Among cannabis users in the United States, roughly one in 7-8 has engaged in medical marijuana use. In relation to location, prevalence proportions reveal important variations across countries and between subgroups within countries. Regarding causes and mechanisms of starting to use cannabis, there is no compelling integrative and replicable conceptual model or theoretical formulation. Most studies of mechanisms have focused upon a ‘gateway sequence’ and person-to-person diffusion, with some recent work on disability-adjusted life years. A brief review of cannabis use consequences, as well as prevention and control strategies is also provided. Conclusion: At present, we know much about the frequency and occurrence of cannabis use, with too little replicable definitive evidence with respect to the other main rubrics. Given a changing regulatory environment for cannabis products, new institutions such as an independent International Cannabis Products Safety Commission may be required to produce evidence required to weigh benefits versus costs. It is not clear that governmentsponsored research will be sufficient to meet consumer demand for balanced points of view and truly definitive evidence.

17 March 2014 in Occupational and Environmental Medicine
Verified
Journal Article
Closed access
PDF file
OAOmayma Alshaarawy
Omayma Alshaarawy
MZMotao Zhu
Motao Zhu
ADAlan M Ducatman
Alan M Ducatman
BCBaqiyyah Conway
Baqiyyah Conway
MAMichael E Andrew
Michael E Andrew
Objective The aim of the current study is to investigate the association of polycyclic aromatic hydrocarbons (PAHs), a group of environmental pollutants, with diabetes mellitus. Animal studies link PAHs to inflammation and subsequent development of diabetes mellitus. In addition, occupational studies suggest that exposure to other aromatic hydrocarbons such as dioxins may be associated with diabetes risk in humans. Design We examined participants from the merged National Health and Nutrition Examination Survey 2001–2002, 2003–2004 and 2005–2006. Exposures of interest were eight urinary monohydroxy-PAHs. Our outcome was diabetes mellitus defined as a glycohemoglobin level (HbA1c) ≥6.5%, a self-reported physician diagnosis of diabetes or use of oral hypoglycaemic medication or insulin. Analyses were adjusted for age, sex, body mass index, race, alcohol consumption, poverty–income ratio, total cholesterol and serum cotinine. Results We observed a positive association between urinary biomarkers of 1 and 2-hydroxynapthol, 2-hydroxyphenanthrene and summed low molecular weight (LMW) PAH biomarkers, and diabetes mellitus. Compared with participants with summed LMW PAH biomarkers in the lowest quartile, the multivariable-adjusted OR of diabetes mellitus among those in the highest quartile was 3.1 (95% CI 1.6 to 5.8). Conclusions Urinary biomarkers of 1 and 2-hydroxynapthol, 2-hydroxyphenanthrene and summed LMW PAH biomarkers are associated with diabetes mellitus in US adults 20–65 years of age. The association of a one-time biomarker of PAH exposure has limitations commonly associated with cross-sectional studies, yet is consistent with experimental animal data and is worthy of additional consideration.